Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GW7647 是一种PPARα有效激动剂,对人 PPARα、PPARγ 和 PPARδ 的EC50值分别为 6、1.1 和 6.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 995 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,990 | 现货 | ||
50 mg | ¥ 4,390 | 现货 | ||
100 mg | ¥ 6,290 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,080 | 现货 |
产品描述 | GW7647 is a potent agonist of PPARα (EC50s: 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ, and PPARδ, respectively). |
靶点活性 | PPARγ:1.1 μM (EC50)( Human PPARγ), PPARα:6 nM (EC50)( Human PPARα), PPARδ:6.2 μM (EC50)( Human PPARδ) |
体外活性 | GW7647 (50 nM) stimulates the PI3K phosphorylation followed by the Akt (Ser473) phosphorylation, which causes NOS1 phosphorylation increased the amounts of NO released in the stripped antral mucosa. GW7647 (50 nM) enhances the initial phase of Ca2+-regulated exocytotic events stimulated by ACh in antral mucous cells, but GW7647 alone does not evoke any exocytotic event. GW7647 (1 μM) induces a significant increase of PDZK1 protein expression to 129.7 ± 6.5% of vehicle treated control in Caco2BBE cells in the absence and presence of IL-1β. GW7647 also decreases the IL-1β-mediated decrease in PDZK1 expression[1]. GW7647 plus ACh stimulates the effects of wortmannin (50 nM) and AKT-inh (100 nM) on the exocytotic events in antral mucous cells[2]. GW 7647 (100 nM) decreases the AQP9 protein abundance by 43%, but it displays not significant effect at 10 and 1,000 nM in WIF-B9 hepatocytes. GW 7647 (100 nM) reduces a 24% reduction in AQP9 protein abundance in HepG2 cells, however, it does not significantly enhance the protein abundance of L-FABP in HepG2 hepatocytes[3]. |
体内活性 | GW7647 (3 mg/kg per day) does not avoid the development of cardiac hypertrophy. It prevents the decline in left ventricular ejection fraction in vivo[4]. |
别名 | 2-[[4-[2-[[环己基氨基)羰基](4-环己基丁基)氨基]乙基]苯基]硫基]-2-甲基丙酸 |
分子量 | 502.75 |
分子式 | C29H46N2O3S |
CAS No. | 265129-71-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (119.34 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9891 mL | 9.9453 mL | 19.8906 mL | 49.7265 mL |
5 mM | 0.3978 mL | 1.9891 mL | 3.9781 mL | 9.9453 mL | |
10 mM | 0.1989 mL | 0.9945 mL | 1.9891 mL | 4.9727 mL | |
20 mM | 0.0995 mL | 0.4973 mL | 0.9945 mL | 2.4863 mL | |
50 mM | 0.0398 mL | 0.1989 mL | 0.3978 mL | 0.9945 mL | |
100 mM | 0.0199 mL | 0.0995 mL | 0.1989 mL | 0.4973 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GW7647 265129-71-3 DNA Damage/DNA Repair Metabolism PPAR inhibit 2-[[4-[2-[[环己基氨基)羰基](4-环己基丁基)氨基]乙基]苯基]硫基]-2-甲基丙酸 GW-7647 GW 7647 Peroxisome proliferator-activated receptors Inhibitor inhibitor